{'fraction_non_alphanumeric': 0.037014207785003236, 'fraction_numerical': 0.02277560329152156, 'mean_word_length': 5.344935471255377, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 2, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Central regulation of energy metabolism by estrogens

Background Estrogenic actions in the brain prevent obesity. Better understanding of the underlying mechanisms may facilitate development of new obesity therapies. Scope of review This review focuses on the critical brain regions that mediate effects of estrogens on food intake and/or energy expenditure, the molecular signals that are involved, and the functional interactions between brain estrogens and other signals modulating metabolism. Body weight regulation by estrogens in male brains will also be discussed. Major conclusions 17β-estradiol acts in the brain to regulate energy homeostasis in both sexes. It can inhibit feeding and stimulate brown adipose tissue thermogenesis. A better understanding of the central actions of 17β-estradiol on energy balance would provide new insight for the development of therapies against obesity in both sexes.


INTRODUCTION
Besides the regulation of the reproductive function, estrogens have a key role in the central regulation of the energy homeostasis including both modulation of feeding behavior and energy expenditure [1e3]. Increased life expectancy implies that many women will live an increasing number of years in a state of ovarian insufficiency. This leads to a steady surge in obesity incidence reaching a staggering figure of more than 70% in women older than 60 years [4]. Although, the interrelationship between estrogen deficiency and obesity was the subject of some discussion, pooled data derived from 107 trials showed that hormone-replacement therapy in menopausal patients led to reduced abdominal obesity, insulin resistance and new-onset diabetes [4], providing a causeeeffect relationship between estrogen deficiency, obesity, and metabolic complications. However, this application has been hampered mainly due to side effects of 17bestradiol, including venous thrombosis and endometrial and breast cancers [5,6]. One solution is to better understand the mechanisms of estrogenic actions, which may facilitate development of novel therapies that provide anti-obesity benefits with fewer side effects. Central action of 17b-estradiol in metabolic control has been a focus of many research groups and has been summarized by a number of recent review articles [7e9]. In this review, we will recap current literature regarding distinct brain regions that mediate 17b-estradiol's effects on feeding and energy expenditure. Importantly, we will discuss advances in our understanding about the molecular signals initiated by 17b-estradiol in neurons that are involved in body weight control. Further, the functional interactions between 17b-estradiol and other appetite-regulatory signals will also be discussed. 17b-estradiol also acts in the peripheral tissues to regulate energy homeostasis, and the audience is directed to read the other excellent reviews in this special issue of Molecular Metabolism.

BRAIN ESTROGENS SUPPRESS FEEDING BEHAVIOR
The anti-obesity actions of estrogens have been well documented. For instance, surgical depletion of endogenous estrogens by ovariectomy (OVX) causes increases in food intake, body weight, and body fat in female animals; 17b-estradiol administration in OVX animals can reduce feeding and prevent obesity [10e15]. Bazedoxifene (a selective estrogen receptor modulator), combined with conjugated equine estrogens, has been used to provide estrogen-mediated benefits while reducing endometrial and breast cancer risk in postmenopausal women [16]. Interestingly, this regimen has been shown to reduce body weight but does not alter feeding in OVX mice [17]. The lack of effect on feeding by the conjugated equine estrogens is likely due to minimal penetration of estrogens to the brain [18], further highlighting the essential actions of brain estrogens in the regulation of feeding. Anti-obesity effects of 17b-estradiol appear to be primarily mediated by estrogen receptor-a (ERa), one of the "classical" estrogen receptors. Mutations in the ERa (Esr1) gene cause obesity in mice and humans [19,20]. Mice lacking ERa are not responsive to anti-obesity effects of 17b-estradiol [12]. In particular, injections of 17b-estradiol into various brain regions decrease food intake in animals [21,22]. These early observations were further supported by findings from genetic mouse models. For instance, Clegg and colleagues generated mice lacking ERa only in the brain, which developed obesity [23]. Increased food intake, low energy expenditure, and low locomotion were observed in these mutant mice [23]. Interestingly, deletion of ERa in the brain also impairs negative feedback regulation by estrogens, resulting in higher 17b-estradiol in blood [23]; yet, the elevated 17bestradiol level in the circulation fails to prevent obesity, suggesting that brain ERa plays a predominant role in the regulation of energy balance. Many brain regions express high levels of ERa, including the arcuate nucleus of hypothalamus (ARC), the nucleus of solitary tract (NTS), the dorsal raphe nuclei (DRN), and the medial preoptic area (MPOA) [24]. As discussed below, recent efforts using genetic mouse models have dissected out the physiological functions of ERa in some of these brain regions in the regulation of energy homeostasis. . These observations indicate that 17b-estradiol can act upon DRN 5-HT neurons to inhibit food intake. Roles of ERa in other brain regions remain elusive. For instance, 17b-estradiol injected directly into the MPOA suppresses feeding [38]. Similarly, suppression of food intake and body weight was observed when OVX female rats received 17b-estradiol implanted in the paraventricular nucleus of the hypothalamus (PVH) [21]. Supporting a role of the PVH, subcutaneous 17b-estradiol administration fails to reduce feeding in rats with the PVH being lesioned [39]. However, findings regarding the PVH were not duplicated by others [40]. Further, it is worth noting that only low levels of ERa are present in the PVH [24]. Importantly, 17b-estradiol is known to regulate foodassociated reward [9], suggesting a role for ERs expressed by brain reward centers, including the nucleus accumbens (NAc) and the lateral hypothalamus (LH) [24]. Indeed, 17b-estradiol was shown to influence metabolism of several monoamines (e.g. dopamine, 5-HT, and norepinephrine) in the NAc [41], although effects of these estrogenic actions in the NAc on feeding behavior remain to be examined. Collectively, the current literature validated a few regions in the female brain (e.g. ARC, NTS and DRN) as important nodes that respond to 17b-estradiol and mediate its signals to suppress feeding; however, the roles of additional brain regions warrant further investigations.

BAT thermogenesis
In mammals, including humans, the main place for adaptive thermogenesis is the brown adipose tissue (BAT) [42e45]. In small mammals living in sub-thermoneutral environment, large quantities of active BAT are encountered [42,43]. In humans, BAT presence was shown to be inversely correlated with increasing age. However, recent evidences have demonstrated the presence of functional brown fat depots in healthy adults [44,46e49]. Histologically, brown adipocytes exhibit numerous small lipid droplets and a very high mitochondrial content. Through the movement of electron across the respiratory chain, the mitochondria produce energy temporarily stored as a proton gradient across the inner mitochondrial membrane. Later, the power derived from this proton gradient is used to generate ATP from ADP by the ATP synthase [50e52]. Alternative pathways, occurring in the internal membrane of BAT's mitochondria and involving the uncoupling protein 1 (UCP1), allow the retrograde transport of protons back into the mitochondrial matrix, sidestepping ATP synthase activity and releasing energy as heat [42,43,53]. BAT is regulated by both the central and peripheral nervous system. The sympathetic nervous system (SNS) has a critical role in BAT thermogenesis stimulation [42,43,45,54e56]. Increased firing rate of the sympathetic nerves subserving BAT induces the secretion of norepinephrine (NE) at the nerve terminal, inducing the subsequent activation of G-protein coupled receptors, named b-adrenergic receptors (b-ARs), expressed in the brown adipocytes; mainly the b 3 subtype (b 3 -AR). The associated G protein coupled to b 3 -AR activates adenylate cyclase (AC), inducing an increase of intracellular cAMP, which subsequently activates protein kinase A (PKA), inducing thermogenesis and downstream activation of p38 mitogen-activated protein kinase (MAPK) [42,45,54]. The acute response of PKA stimulates lipolysis leading to elevated cytosolic free fatty acid (FFA) levels. This FFA increase will occur following the sequential hydrolysis of triglycerides by the adipose triglyceride lipase (ATGL), the hormonesensitive lipase (HSL; being pHSL the activated form), and the monoacylglycerol lipase (MGL). The FFAs-CoA -FFAs activated to acyl CoAs by acyl-CoA synthetase -are transferred into the mitochondria by the carnitine palmitoyltransferase 1a (CPT1a), where FA oxidation induces NADH and FADH production, which will be oxidized later in the electron transport chain [42,43,45,54].
3.2. Direct effects of 17b-estradiol on BAT For the first time, in the 70s, it was shown that 17b-estradiol could bind to both interscapular brown and white adipocytes [57]. Physiological evidence demonstrated that 17b-estradiol could lead to elevated energy expenditure in rodents -hamsters, rats, and micethrough an increase of BAT lipolysis and thermogenesis [58e62]. Notably, those effects were related to an increased NE turnover that was reduced by OVX [63], suggesting not only a direct action of 17bestradiol on BAT but also an indirect regulatory action on the central control of the sympathetic firing on BAT. This modulatory mechanism would be comparable to the effects observed with thyroid hormones (THs), which, in addition to stimulating UCP1 expression, also induce NE-induced lipolysis [64e67]. However, it has also been demonstrated that the direct effect of 17b-estradiol on BAT is more likely due to modulations in (i) adrenergic receptors (AR) and mitochondrial biogenesis-signaling factors, such as phosphatase and tensin homolog (PTEN), (ii) nuclear respiratory transcriptional factor 1 (NRF1), and (iii) probably peroxisome proliferator-activated receptor g coactivator-1a (PGC-1a), rather than to modifications in UCP1 expression [68e70]. Studies have provided strong evidences that ERs are expressed in a sex-dependent manner by the brown adipocytes, with higher ERa densities in male than female rats [71]. However, phenotype studies of ERa knockout mice have not provided conclusive data on any possible direct role of estrogens on BAT. Moreover, evidences were released demonstrating that ERa knockout mice display an age-dependent increased adiposity -associated with both hyperplasia and hypertrophy -of white fat depots. Conversely, despite impaired energy expenditure, no such differences were observed in the BAT (neither in male nor females) suggesting the possible existence of central effects [20,72]. Nevertheless, the deletion of ERb does not induce obesity or metabolic alterations in standard diet fed mice kept at 25 C. However, animals fed with high-fat diet (HFD) exhibit an elevated body weight and an enlarged adiposity than their wild types kept at 25 C [73]. Alternatively, aromatase knockout (ArKO) mice display larger BAT pads, reversed by peripheral 17b-estradiol treatment [74]. Concerning G protein-coupled estrogen receptor (GPER) implications in metabolism, it has been shown that mice -independently of the genderlacking GPER show mild obesity associated with (i) decreased energy expenditure, (ii) enlarged BAT lipid content (suggesting a reduced thermogenic activity), and (iii) decreased expression of UCP1 and b 3 -AR when kept at 23-24 C [75]. Until recently, the implication of ERs in human BAT had not been investigated deeply. As reported in 2014, both ERa and ERb were found to be expressed in human fetal BAT, with higher ERa expression [76]. Although the role of ERs in adult human BAT remains undefined, the discovery of functional BAT in adulthood [44,46e49] suggests a possible implication of estrogens in human brown fat activity regulation. In line with those findings, recent studies showed that there is more functionally active brown adipose tissue present in women (greater 18 F-fluorodeoxyglucose ( 18 F-FDG) uptake) than in men, physiologically correlated with higher BAT activity [46]. This suggested sexual dimorphism indicates a possible direct modulation of human BAT by gonadal steroids, including estrogens.

Central effects of 17b-estradiol on BAT
The ventromedial nucleus of hypothalamus (VMH) was the first hypothalamic nucleus identified regulating energy expenditure, particularly in thermogenesis. Notably, the ERa is highly expressed in the VMH, suggesting estrogenic functional relevance [77,78]. In addition, as demonstrated by diverse electrical, pharmacological, or hormonal stimulations of the VMH inducing an increase of BAT temperature, the VMH has an important role in energy expenditure modulation, mostly through the SNS [79e85] (for review [42,45,55,86]). According to those findings, VMH neurons were also described to communicate with nuclei functionally linked to the modulation of BAT activity, such as the raphe pallidus (RPa) and inferior olive (IO), to increase the accuracy of SNS activity modulation [42,45,55] ( Figure 1). Electrophysiological studies showed that 17b-estradiol could also modulate the excitability of VMH neurons through a mechanism specifically dependent of cAMP [87]. Later, Clegg and colleagues provided strong evidence showing that the VMH is as major hypothalamic center mediating estrogen's effect on energy expenditure. They reported that VMH-specific silencing of ERa elicited obesity, hyperglycemia, and decreased energy expenditure either in mice and rats [88]. Further studies showed that the action of 17b-estradiol on thermogenesis depends on steroidogenic factor-1 (SF1) neurons of the VMH. As reported, female (not male) ERa/SF1 null mice fed with a normal diet exhibited a food intake-independent increase of body weight associated to visceral adiposity, which was increased when animals were fed with HFD [23]. Of note, that phenotype was linked to a lower metabolic rate, impaired BAT thermogenesis and subsequently diminished heat production in mice maintained at 22 C. In keeping with this, the specific depletion of ERa in SF1 neurons in mice induced a reduced sympathetic outflow on BAT and lower expression of UCP1, peroxisome proliferator-activated receptor gamma (PPARg), PGC-1a, and b 3 -AR in BAT [23]. Accordingly, the simultaneous deletion of ERa in SF1 and POMC neurons has been shown to induce hypometabolism, hyperphagia, and severe obesity [23]. However, as demonstrated by the treatment with an ERb-selective agonist in female mice under HFD inducing an increased expression of UCP1 in BAT and reduced obesity, it is likely that some of 17b-estradiol effects on BAT thermoregulation could be mediated by ERb [89]. Current data have also described a new subset of ERa positive neurons in the ventrolateral region of the ventromedial hypothalamus (VMH vl ) that promotes hormone-dependent female locomotor activity [90]. The impaired development of those neurons elicits inactivity and obesity, without changes in BAT thermogenesis below thermoneutrality [90]; overall, this evidence suggests that 17b-estradiol likely induces specific effects on energy homeostasis depending on the targeted VMH neuronal populations. Recently, AMP-activated protein kinase (AMPK), a cellular energy sensor [91], has been described to be the principal molecular mediator of 17b-estradiol's actions within the VMH. Stereotaxic microinjections of 17b-estradiol in the VMH at non-thermoneutral conditions induce multiple effects: (i) a catabolic response associated with increased neuronal firing in the RPa and IO, (ii) an increased sympathetic tone, (iii) higher BAT and body temperatures, and (iv) increased energy expenditure and lower respiratory quotient (RQ), all of which lead to body weight decrease. Interestingly, these 17b-estradiol-mediated effects were correlated with an inhibition of hypothalamic AMPK function, specifically in the VMH, but not in the ARC [85]. Remarkably, the 17b-estradiol-induced activation of BAT thermogenesis associated with body weight loss could be prevented by the genetic re-activation of AMPK in the VMH [85]. Notably, it has been reported recently that other molecules implicated in the modulation of BAT activity, such as leptin, THs, bone morphogenetic protein 8b (BMP8b), and glucagonlike peptide 1 (GLP1) [81,82,86,92e97] are also sharing this AMPK(VMH)-SNS-BAT axis to mediate their effects, suggesting that this could represent a canonical mechanism modulating energy balance [45,91]. This indicates that the axis might be a suitable target for the treatment of obesity, such as after ovariectomy and/or during menopausal states [2,91,98e100]. However, it is worth mentioning that although the central effects of 17b-estradiol on BAT thermogenesis are preserved in diet-induced obese models feeding a HFD at 24 C [101], they disappear during pregnancy. Actually, despite the fact that hypothalamic AMPK has been reported to be inhibited by 17b-estradiol during gestation, pregnant rats exhibit lower temperature and BAT function, as well as hyperphagia [78]. The mechanistic details of these effects remain unclear, but they are associated with reduced POMC expression (which would be under the increased appetite) and decreased UCP1 and b3-AR expression in BAT at non thermoneutral housing temperatures [78]. These data indicate that pregnancy elicits a state of resistance to the central actions of 17b-estradiol on BAT thermogenesis, which is likely required to maintain a positive energy balance essential to successfully endure the energetic demands of embryonic development. Besides BAT thermogenesis, AMPK may be important for understanding estrogen actions on glucose homeostasis. Hypothalamic AMPK, particularly in the VMH, has been demonstrated to have a key role in hypoglycemia sensing and the regulation of counterregulatory responses, such as increased levels of corticosterone, glucagon, and catecholamines [102e105]. Current evidence has shown that estradiol controls hypothalamic astrocyte AMPK and hindbrain catecholaminedependent activation of this cell-specific sensor by hypoglycemia [106]. In keeping with this evidence, recent data have also proposed that 17b-estradiol acting on AMPK in the hindbrain dorsal vagal complex (DVC) might be also involved in the induction of counterregulatory responses [107]. Although these data are of relevance, further work involving genetic models will be necessary to address the physiological relevance of estrogen on AMPK-induced effects on glucose homeostasis.

ESTROGEN-COUPLED INTRACELLULAR SIGNALS
One major question in the field is what estrogen-initiated molecular signals mediate its anti-obesity functions. ER-initiated signals are known to include several distinct pathways. As classic nuclear receptors, ERs can directly bind to estrogen-responsive element (ERE) on DNA to regulate expression of its target genes. Interestingly, a mutation in the DNA binding domain of ERa does not affect energy homeostasis in female mice [108], despite the fact that this mutation diminishes ERa 0 s binding to the ERE motifs on the chromosome [109]. Thus, the ERE-dependent ERa functions do not appear to be essential for energy balance. However, Handgraaf et al. developed mice with mutations in the activation function motif-2 (AF-2), which is required for transcriptional activity of ERa; these mutation causes obesity and diabetes in mice [110], suggesting that transcriptional activity of ERa, perhaps through ERE-independent mechanisms, is important for body weight control. In parallel, it has been increasingly appreciated that a portion of ER molecules exist on the cytomembrane and in the cytosol, and these ERs can trigger rapid signaling cascades, e.g. PI3K/Akt. Indeed, ARC POMC neurons are shown to acutely (in the time scale of milliseconds) respond to 17b-estradiol with increased firing and depolarization, and these responses are mediated by an ERa-PI3K-mediated mechanism [29,30]. Further, female mice lacking the catalytic PI3K subunit selectively in ARC POMC neurons are less responsive to anti-obesity effects of 17b-estradiol [30,111]. However, when the full length ERa protein is replaced by a ERa domain that exists on the cytomembrane and retains capacity of initiating rapid signals (e.g. PI3K), mice display a similar obesity as seen in ERa knockout mice [112]. Thus, the ERa-initiated rapid signaling may not be sufficient to prevent obesity. Nevertheless, anti-obesity effects of estrogens appear to require not only ERa-initiated rapid signaling pathways but also ERa 0 s transcriptional activity. The detailed intracellular ERa functions that regulate energy balance remain to be fully revealed.

Leptin
Leptin is an adipocyte-derived hormone that reflects energy storage [113]. Leptin prevents body weight gain through suppressing feeding [114,115] and increasing energy expenditure [116e118]. The long form leptin receptor (also known as LEPR-B) mediates effects of leptin on body weight [119], and the majority of leptin's actions are mediated by LEPR-B in the brain [120]. Many hypothalamic nuclei, including the ARC, express abundant LEPR-B. In particular, some ARC neurons expressing LEPR-B also co-express ERa [121], and 17b-estradiol can alter LEPR-B mRNA levels in the ARC [122]. Thus, 17b-estradiol and leptin may interact within ARC neurons. Indeed, enhanced leptin sensitivity is correlated with increased 17b-estradiol levels; on the other hand, surgical depletion of ovarian hormones reduces leptin sensitivity, which can be rescued by 17b-estradiol treatment [123].

Cholecystokinin
CCK is synthesized and released by the proximal intestine. CCK acts upon CCK-A receptors to trigger satiety signal and suppress feeding [124]. Increased 17b-estradiol can potentiate CCK's effects to suppress feeding [33,125e127], and this effect is shown to be mediated through enhanced sensitivity of vagal CCK-A receptors [126,128,129]. CCK decreases meal size, which is associated with increased c-fos expression (a marker for neuronal activation) after feeding [130e133] or CCK treatment [134,135]. Interestingly, 17b-estradiol potentiates cfos expression in the NTS, the PVH, and the central nucleus of the amygdala evoked by meals or by CCK treatment [131,136]. Thus, 17b-estradiol decreases meal size partly through potentiating satiety signals evoked by CCK. However, it needs to be pointed out that the phasic meal size reduction during the estrus in gonad-intact female rats can only be partially attenuated but not be fully blocked by a CCK antagonist [127], indicating that other mechanisms/signals are involved in the phasic regulation of feeding across the estrous cycle.

Ghrelin
Ghrelin is a stomach-derived hormone, which stimulates feeding via its growth hormone secretagogue receptors (GHSRs) [137e142]. Interestingly, effectiveness of ghrelin to promote feeding is less robust in gonad-intact female rats than in male rats or in female rats depleted of ovarian hormones [143]. In gonad-intact female rats, ghrelin significantly increases food intake during the diestrus when 17b-estradiol is low, but this effect is not observed during the proestrus or estrus when 17b-estradiol is high [143]. In addition, male rats receiving 17bestradiol also show decreased orexigenic responses to ghrelin treatment [143]. Interestingly, while depletion of ovarian hormones increases feeding and body weight in wild type female mice, these effects are blunted in mice lacking GHSR [143]. Thus, effects of 17bestradiol to suppress feeding appear to require intact ghrelin signaling [143], although the detailed mechanisms for this functional interaction remains unclear.

Central melanocortin system
Neurons that produce endogenous melanocortins and downstream neurons that express melanocortin receptors are known to play essential roles in body weight control [144e148]. The melanocortin neurons include POMC neurons and agouti-related peptide (AgRP) neurons, and both these populations are located within the ARC. POMC neurons secret a-melanocyte-stimulating hormone (a-MSH) to stimulate melanocortin receptors and suppress body weight gain; on the other hand, AgRP functions as an endogenous antagonist of melanocortin receptors to promote weight gain [144e146]. 17b-estradiol has been shown to regulate POMC expression levels. For instance, depletion of ovarian hormones reduces POMC mRNA levels in female animals, but this response can be reversed by 17b-estradiol [85,149]. Decreased POMC levels are also observed in mice lacking ERa [150]. In addition, the number of excitatory synaptic inputs to ARC POMC neurons is highest during the proestrus [28]. Further, it has been shown that 17b-estradiol acutely stimulates firing of POMC neurons [29,30,151]. Thus, 17b-estradiol appears to regulate both POMC expression and excitability of POMC neurons, two essential functions of these neurons to regulate body weight balance.

NPY
ARC AgRP neurons also co-release neuropeptide Y (NPY), which is a potent orexigenic signal that promotes feeding [152,153]. Expression of NPY and AgRP in the hypothalamus is at the lowest level during estrus in female mice [154]. 17b-estradiol decreases activity of NPY/ AgRP neurons and reduces hunger-driven feeding [154]. Importantly, ablation of NPY/AgRP neurons attenuates the estrus-dependent feeding fluctuations and anorexia induced by 17b-estradiol [154]. Thus, NPY/AgRP neurons are functionally involved in 17b-estradiol's actions to suppress feeding.

Serotonin
Brain 5-HT, primarily synthesized by DRN neurons [155], plays important roles in feeding control. Meals enhance brain 5-HT content, whereas hunger suppresses it [156]. Pharmacological agents that increase brain 5-HT content, e.g. d-fenfluramine (d-Fen) [157], decrease food intake in rodents and humans [158e160]. On the other hand, blockade of 5-HT signals in the brain leads to increased food intake and weight gain [161e164]. 17b-estradiol increases the expression of the serotonin transporter, which may result in enhanced brain 5-HT bioavailability [165]. Indeed, 5-HT-induced anorexia is potentiated by 17b-estradiol treatment [166]. As mentioned above, loss of ERa selectively in 5-HT neurons blunts effects of 17b-estradiol to inhibit binge-like eating in mice [35]. Thus, 17b-estradiol and 5-HT interact within the brain to provide synergistic effects to inhibit feeding.

ESTROGENIC ACTIONS IN MALE BRAINS
Male animals also need estrogens to maintain normal body weight. For instance, deletion of ERa causes obesity in male mice [20,167]; ERa mutation also leads to obesity in men [168,169]. Treatment with 17b-estradiol or its analogs decreases body weight in male animals [28,98]. Testosterone, as a male sex hormone, can be converted into 17b-estradiol by aromatase. Thus, aromatase knockout mice represent a good model to examine functions of endogenous estrogens not only in female but also in male animals. Female aromatase knockout mice show increased body weight from 3 months of age, while male mutant mice show late onset obesity one year later [170]. Both male and female aromatase knockout mice show increased gonadal and infrarenal fat pads compared to control littermates. This increased adiposity is associated with reduced spontaneous physical activity levels, reduced glucose oxidation, and a decrease in lean body mass [170]. These findings indicate that endogenous estrogens prevent obesity in both sexes, but the underlying mechanisms may not be identical. Tissues that express aromatase include not only the gonads but also the breast, brain, muscle, bone, and adipose tissue [171e173]. Notably, abundant aromatase is expressed in a few brain regions, including the medial amygdala (MeA), the bed nucleus of stria terminalis, the septum, and the pre-optic area [174]. Thus, despite the lack of circulating estrogens, these brain regions in males could be exposed to high levels of 17b-estradiol. In fact, deletion of ERa selectively in the MeA leads to obesity in both female mice and male mice [175]. Thus, it is conceivable that ER populations in brain regions or peripheral tissues with aromatase activity may play important roles in the regulation of energy balance in both sexes. This possibility needs further investigation.

ESTROGENIC ACTIONS IN DEVELOPING BRAINS
The critical brain regions regulating energy balance (e.g. the hypothalamus) are structurally and functionally immature at birth [176]. In rodents, the basic anatomy of the hypothalamus is formed between embryonic day 12e15, and neurochemical identities of most of hypothalamic neurons are established before birth [176]. However, the majority of neural innervations to or from the hypothalamus do not fully develop till about postnatal day 21 [177e179]. After weaning, hypothalamic neurons still undergo substantial remodeling [180]. Events (e.g. nutrition and hormone milieu) during this critical window have profound effects on the development of neural circuits controlling body weight and program energy balance later in life [181]. Despite the well-known anti-obesity effects of estrogens in adults, their roles in the metabolic programming are not fully understood. Emerging evidence suggests that ERa in developing brains may program energy balance. For example, rodent brains start to express ERa at E21 [182]. The number of ERa neurons increases postnatally (P0-P35) in key hypothalamic regions that are relevant to energy balance, including the ARC and VMH [183]. Further, rodents experience a transient estrogen surge in the brain immediately after birth [184,185]. Similar estrogen surges have been reported in infant boys and girls (1e6 months) [186]. Another estrogen surge occurs prior to the onset of puberty [187,188]. Both these P0 and pre-pubertal, endogenous, estrogen surges could exert profound effects on brain development. Indeed, manipulations of testosterone in male and female rat pups, which presumably alter estrogens originating from aromatization, lead to permanent changes in synaptological morphology and neural excitability of ARC neurons [189]. Further, postnatal manipulations of gonadal steroids permanently alter feeding behavior and body weight in adults [190,191]. In addition, it has been reported that genetic effects on eating disorders are significantly stronger in post-pubertal girls than in pre-pubertal girls [192,193], suggesting a potential effect of sex hormones (e.g. estrogens) on feeding behavior specifically during the puberty development. Collectively, the current literature suggests robust effects of estrogens on developmental programming of energy balance, but the detailed mechanisms for such effects require further investigations.

CONCLUSIONS
17b-estradiol's actions in the brain contribute to the regulation of energy homeostasis in both sexes, although its actions in females are more extensively explored. Multiple brain regions that express high levels of ERa mediate the effects of 17b-estradiol to inhibit feeding; 17b-estradiol stimulates BAT thermogenesis primarily via its actions in the VMH. Both rapid signals and "classic" transcriptional activities of 17b-estradiol are involved in body weight control; however, the detailed molecular mechanisms remain unclear. 17b-estradiol has broad interactions with many other body weight-regulatory signals, and these interactions provide a coordinated control of feeding behavior and body weight. Further, 17b-estradiol can be locally produced in male brain regions with aromatase activity and exerts physiologically relevant functions to maintain body weight balance, and these estrogenic functions in male brains remain to be further explored. de la Obesidad y Nutrición is an initiative of ISCIII. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

CONFLICT OF INTEREST
There are no known conflicts of interest.